Hematological hypereosinophilia

IF 0.4 4区医学 Q4 MEDICAL LABORATORY TECHNOLOGY

Annales de biologie clinique Pub Date : 2022-07-01 DOI:10.1684/abc.2022.1731

Ines Ghariani, Oumaima Mahmoud, Saloua Hamzaoui, Néjia Braham, Leila Bekir

{"title":"Hematological hypereosinophilia","authors":"Ines Ghariani, Oumaima Mahmoud, Saloua Hamzaoui, Néjia Braham, Leila Bekir","doi":"10.1684/abc.2022.1731","DOIUrl":null,"url":null,"abstract":"Introduction: Hematological disorders are the third cause of hypereosinophilia, after allergic and parasitic disease. The objective of our study is to show the epidemiological, clinical, biological and therapeutic characteristics of hematological hypereosinophilia.Patients and methods: This is a retrospective study over a 4-year period (March 2017-March 2021) concerning 14 patients with hematological hypereosinophilia.Results: Fourteen patients were included (9 women and 5 men). The median age at diagnosis was 55 years. Hematological hypereosinophilia was mainly of clonal etiology. Clinical manifestations were either specific to hypereosinophilia, such as organ damage, or related to the etiology of hypereosinophilia, such as hepato-splenomegaly and lymphadenopathy. Moderate and severe forms were the most commonly reported. Several other quantitative and qualitative abnormalities of the blood picture were reported. Identification of the FIP1L1-PDGFRA fusion gene by molecular biology (RT-PCR) was positive in two patients. Imatinib was the main treatment for clonal forms.Conclusion: Hematological hypereosinophilia is a rare and complex pathology. Our study has confirmed this epidemiological, clinical, biological and therapeutic heterogeneity and has enabled us to realize the contribution of molecular biology in the diagnosis and the treatment of hypereosinophilia.","PeriodicalId":7892,"journal":{"name":"Annales de biologie clinique","volume":"80 4","pages":"355-362"},"PeriodicalIF":0.4000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annales de biologie clinique","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1684/abc.2022.1731","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Hematological disorders are the third cause of hypereosinophilia, after allergic and parasitic disease. The objective of our study is to show the epidemiological, clinical, biological and therapeutic characteristics of hematological hypereosinophilia.

Patients and methods: This is a retrospective study over a 4-year period (March 2017-March 2021) concerning 14 patients with hematological hypereosinophilia.

Results: Fourteen patients were included (9 women and 5 men). The median age at diagnosis was 55 years. Hematological hypereosinophilia was mainly of clonal etiology. Clinical manifestations were either specific to hypereosinophilia, such as organ damage, or related to the etiology of hypereosinophilia, such as hepato-splenomegaly and lymphadenopathy. Moderate and severe forms were the most commonly reported. Several other quantitative and qualitative abnormalities of the blood picture were reported. Identification of the FIP1L1-PDGFRA fusion gene by molecular biology (RT-PCR) was positive in two patients. Imatinib was the main treatment for clonal forms.

Conclusion: Hematological hypereosinophilia is a rare and complex pathology. Our study has confirmed this epidemiological, clinical, biological and therapeutic heterogeneity and has enabled us to realize the contribution of molecular biology in the diagnosis and the treatment of hypereosinophilia.

查看原文本刊更多论文

血液学嗜酸性粒细胞增多

简介:血液病是继过敏性和寄生虫病之后嗜酸性粒细胞增多症的第三大原因。我们的研究目的是显示血液学嗜酸性细胞增多症的流行病学、临床、生物学和治疗特点。患者和方法:这是一项为期4年(2017年3月- 2021年3月)的回顾性研究，涉及14例血液学嗜酸性细胞增多症患者。结果:共纳入14例患者(女9例，男5例)。诊断时的中位年龄为55岁。血液学嗜酸性细胞增多主要为克隆性病因。临床表现为嗜酸性细胞增多症特有的，如器官损害，或与嗜酸性细胞增多症的病因有关，如肝脾肿大和淋巴结病。中度和重度形式是最常见的报告。报告了其他几个定量和定性的血液图像异常。2例患者经分子生物学(RT-PCR)鉴定为FIP1L1-PDGFRA融合基因阳性。伊马替尼是克隆型的主要治疗方法。结论:血液学嗜酸性细胞增多症是一种罕见而复杂的病理。我们的研究证实了这种流行病学、临床、生物学和治疗的异质性，并使我们认识到分子生物学在嗜酸性粒细胞增多症的诊断和治疗中的贡献。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annales de biologie clinique 医学-医学：研究与实验

CiteScore

0.80

自引率

20.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Multidisciplinary information with direct relevance to everyday practice Annales de Biologie Clinique, the official journal of the French Society of Clinical Biology (SFBC), supports biologists in areas including continuing education, laboratory accreditation and technique validation. With original articles, abstracts and accounts of everyday practice, the journal provides details of advances in knowledge, techniques and equipment, as well as a forum for discussion open to the entire community.